Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch
of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution).
Glenmark's Travoprost Ophthalmic Solution USP, 0.004%
is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z®2 Ophthalmic Solution USP, 0.004% of Sandoz, Inc.
According to IQVIATM sales data for the 12-month period ending September 2024, the Travatan Z® Ophthalmic Solution USP, 0.004% market achieved annual sales of approximately $66.2 million.